Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Achilles Therapeutics plc (NASDAQ: ACHL) had its price target lowered by analysts at Chardan Capital from $11.00 to $6.00. They now have a "buy" rating on the stock.
Achilles Therapeutics plc (NASDAQ: ACHL) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating. They now have a $2.00 price target on the stock, down previously from $8.00.